G2GBIO Hits Limit-Up on China Partnership; Inventera Gains on U.S. Clinical Trial Clearance [K-Bio...
Predicted impact: Low
US Phase 1 trial approval already reported in the past 14 days; small company with no revenue.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.